244 results
Page 2 of 13
8-K
EX-99.1
i7kcui ijp
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
7:40am
8-K
EX-2.1
7up9i4ah
5 Dec 22
Completion of Acquisition or Disposition of Assets
4:16pm
8-K
EX-99.1
r001vbjmn
9 Nov 22
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
4:07pm
8-K
EX-99.1
utp u15mcerzda8
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:59am
8-K
EX-99.1
3yd8rvv3
3 Aug 22
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
4:07pm
DEFA14A
olmyvrw6fr 1ll
17 Jun 22
Additional proxy soliciting materials
4:09pm
8-K
EX-99.1
rd4h7 ax6b4w
4 May 22
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
4:17pm
8-K
EX-99.1
yaeormhshe9ng
4 May 22
Jazz Pharmaceuticals Announces First Quarter 2022
4:13pm
8-K
EX-99.1
sccd01q7dq jap9q5qm
7 Apr 22
Other Events
7:15am
8-K
EX-99.1
nscupw
1 Mar 22
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2021
4:07pm
8-K
EX-99.1
weyhf08q6lnc
10 Jan 22
Announces $5 billion revenue target for 2025
7:47am
8-K
EX-99.1
tnrqmk6wv9b7wgn
9 Nov 21
Jazz Pharmaceuticals Announces Third Quarter 2021
4:07pm